Bilaketaren emaitzak - Merle Schanz

  • Erakusten 1 - 7 emaitzak -- 7
Findu emaitzak
  1. 1
    Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?

    Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? nork Harini Subbaraman, Merle Schanz, Alexandra Trkola

    Argitaratua 2018-07-01
    Testu osoa
    Artikulua
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.

    Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent. nork Lucia Reh, Carsten Magnus, Merle Schanz, Jacqueline Weber, Therese Uhr, Peter Rusert, Alexandra Trkola

    Argitaratua 2015-07-01
    Testu osoa
    Artikulua
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies.

    Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. nork Irene A Abela, Livia Berlinger, Merle Schanz, Lucy Reynell, Huldrych F Günthard, Peter Rusert, Alexandra Trkola

    Argitaratua 2012-01-01
    Testu osoa
    Artikulua
    Gogokoenen artean sartu
    Gorde:
  4. 4
    High-throughput sequencing of human immunoglobulin variable regions with subtype identification.

    High-throughput sequencing of human immunoglobulin variable regions with subtype identification. nork Merle Schanz, Thomas Liechti, Osvaldo Zagordi, Enkelejda Miho, Sai T Reddy, Huldrych F Günthard, Alexandra Trkola, Michael Huber

    Argitaratua 2014-01-01
    Testu osoa
    Artikulua
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines

    Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines nork Magdalena Schwarzmüller, Cristina Lozano, Merle Schanz, Irene A. Abela, Silvan Grosse-Holz, Selina Epp, Martina Curcio, Jule Greshake, Peter Rusert, Michael Huber, Roger D. Kouyos, Huldrych F. Günthard, Alexandra Trkola

    Argitaratua 2024-09-01
    Testu osoa
    Artikulua
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland

    Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland nork Sarah R Haile, Milo Alan Puhan, Anja Frei, Agne Ulyte, Christoph Berger, Susi Kriemler, Thomas Radtke, Michael Huber, Merle Schanz, Magdalena Schwarzmueller, Alexandra Trkola, Irene Alma Abela, Jacob Blankenberger, Ruedi Jung, Celine Capelli

    Argitaratua 2021-07-01
    Testu osoa
    Artikulua
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Assessing immunogenicity barriers of the HIV-1 envelope trimer

    Assessing immunogenicity barriers of the HIV-1 envelope trimer nork Liridona Maliqi, Nikolas Friedrich, Matthias Glögl, Stefan Schmutz, Daniel Schmidt, Peter Rusert, Merle Schanz, Maryam Zaheri, Chloé Pasin, Cyrille Niklaus, Caio Foulkes, Thomas Reinberg, Birgit Dreier, Irene Abela, David Peterhoff, Alexandra Hauser, Roger D. Kouyos, Huldrych F. Günthard, Marit J. van Gils, Rogier W. Sanders, Ralf Wagner, Andreas Plückthun, Alexandra Trkola

    Argitaratua 2023-09-01
    Testu osoa
    Artikulua
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: